SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Nayax reported second quarter 2026 financial results with revenue of $122.6–$123 million (28% year-over-year growth), net loss of $10.1 million, and Adjusted EBITDA of $14.1 million (12% growth). The company reaffirmed full-year 2026 guidance and disclosed key operational metrics including recurring revenue of $87.7 million (24% growth).
View raw filing on EDGAR →The exhibit announces that TJGC Group Limited is negotiating a potential intellectual property license agreement with a robotics technology provider for non-exclusive, worldwide rights to commercialize AI and robotics technologies. The company states this aligns with its intelligent automation strategy and would enhance its technology portfolio. While the agreement is not yet definitive ("There is no assurance the parties will reach a definitive agreement"), the announcement of material strategic negotiations for technology licensing that could expand the company's product portfolio and business direction constitutes a material operational event that would affect a reasonable investor's assessment of the company's growth prospects and strategic direction.
View raw filing on EDGAR →The filing discloses the appointment of Qunxue Yin as Chief Executive Officer and Chairman of the Board effective immediately on August 8, 2026, following the resignation of Jialuan Ma on August 6, 2026. While both a departure and appointment occur, the principal disclosed action centers on the appointment of a new CEO and Chairman with detailed biographical information and qualifications. This is material as it represents a change in the Company's principal executive officer and board leadership.
View raw filing on EDGAR →The letter discloses multiple executive leadership transitions effective December 31, 2026 and August 3, 2026: Vivek Bantwal becomes sole Chief Executive Officer of the Goldman Sachs BDC complex; Justin Betzen becomes Co-President and Co-Chief Operating Officer alongside Tucker Greene; and Greg Watts and Steven Budig are elevated to co-heads of Americas Direct Lending. While David Miller's departure as Co-CEO is also mentioned, the primary focus and substance of the disclosure centers on the appointments and promotions of these executives into expanded roles, making exec_appointment the most salient classification.
View raw filing on EDGAR →The filing discloses a postponement of Q2 2026 earnings reporting and conference call due to complexity in finalizing tax accounting treatment related to a refinancing and debt restructuring completed in Q2 2026. While the postponement itself is administrative, the underlying trigger—unresolved tax accounting issues from material debt restructuring—signals potential accounting complexity or uncertainty that could affect investor assessment. This does not fit neatly into earnings_release (no results disclosed), restatement (no non-reliance stated), or debt_issuance (the debt activity already occurred); it is a disclosure of delay in financial reporting tied to unresolved accounting treatment, making it material but difficult to classify into a specific category.
View raw filing on EDGAR →This is a monthly revenue announcement disclosing July 2026 consolidated revenue of NT$2,823.0 million (US$87.5 million), representing a 43.6% year-over-year increase and a record high monthly revenue since 2014. The press release explicitly states "ChipMOS REPORTS 43.6% YoY INCREASE IN JULY 2026 REVENUE" and notes strong AI-related demand driving the results. While monthly revenue disclosures are less common than quarterly earnings, this announcement of material revenue growth and record performance would affect a reasonable investor's assessment of the company's operational momentum and financial health.
View raw filing on EDGAR →Jeff D. Martinez was appointed as Senior Vice President, Utility Operations effective October 1, 2026, with a salary increase from $380,000 to $500,000, joining the Management Committee. James H. Jeffries IV was elected to the Board of Directors effective September 1, 2026. John S. McDill announced his retirement as Senior Vice President, Utility Operations in early 2027.
View raw filing on EDGAR →Natuzzi announces it has "signed a commitment letter with a candidate for the role of Chief Executive Officer." While the appointment is not yet finalized (it is a commitment letter with a candidate, not a completed appointment), the disclosure of a CEO succession process is material to investors assessing leadership continuity and strategic direction. The company emphasizes the candidate's "extensive international experience" and belief that his profile will support "ongoing restructuring process and long-term strategic development," indicating this is a significant governance event. The language suggests an imminent appointment rather than a speculative search.
View raw filing on EDGAR →ReNew Energy announced the sale of 1,055 MW of solar and wind projects across Rajasthan and Karnataka to PGPPL (a CESC Limited subsidiary) at an enterprise value of approximately $532 million, with a definitive agreement signed on August 10, 2026. This is a material disposition of operating assets with significant cash inflow implications (~$190 million projected), representing a substantial reduction in ReNew's generation portfolio and warranting disclosure as a material acquisition/disposition event.
View raw filing on EDGAR →P. Barrett Brown, Executive Vice President and former President of the Retail Segment and a named executive officer, voluntarily resigned from all officer and director positions effective August 10, 2026, pursuant to a Transition Agreement. While the agreement includes compensatory arrangements (base salary continuation, bonuses, severance totaling approximately $3.93 million), the principal disclosed action is the departure of a senior named executive officer, making exec_departure the most salient classification.
View raw filing on EDGAR →SK hynix disclosed that it is reviewing measures to strengthen its packaging business competitiveness, including potential sale of an ownership stake in its Chongqing packaging plant (valued at approximately Won 4 trillion). While no specific transaction has been determined, the scale and strategic nature of a potential divestiture of a major manufacturing asset would materially affect investor assessment of the company's capital allocation and operational footprint. This is a response to a Korea Exchange disclosure inquiry regarding media reports of the potential transaction.
View raw filing on EDGAR →This is a classic earnings release disclosure under Item 2.02. The press release announces "financial results for its fiscal 2026 third quarter ended June 30, 2026" with specific financial metrics including R&D expenses, G&A expenses, operating loss, net loss per share, and balance sheet information (cash position). The filing explicitly states the press release is "furnished pursuant to Item 2.02 of Form 8-K" and is attached as Exhibit 99.1, which is the standard format for quarterly earnings announcements.
View raw filing on EDGAR →The filing discloses the appointment of two new directors, David Benson and David Cush, to SAIC's Board effective August 20, 2026, with the Board size increasing from ten to twelve members. Both appointees bring substantial executive and board experience (Benson from Fannie Mae and Merrill Lynch; Cush from Virgin America and American Airlines), and will serve on key committees including the Audit Committee. This is a material governance event affecting board composition and oversight structure.
View raw filing on EDGAR →Christopher Neczypor, Executive Vice President and Chief Financial Officer, notified the Company on August 6, 2026 of his intention to leave to pursue another employment opportunity. Adam M. Cohen was appointed as interim CFO to manage the transition.
View raw filing on EDGAR →CECO Environmental issued a press release on August 10, 2026 announcing its financial results for the second quarter ended June 30, 2026, including revenue of $285.0 million (up 54%), net loss of $(34.8) million, and adjusted EBITDA of $40.2 million (up 73%). The company also raised its full-year 2026 consolidated outlook. This is a standard quarterly earnings disclosure furnished under Item 2.02 with consolidated financial statements and reconciliations of GAAP to non-GAAP measures.
View raw filing on EDGAR →Silicon Motion announced a proposed offering of $800 million aggregate principal amount of 0.00% convertible senior notes due 2031, with an additional $120 million option for initial purchasers. This is a material creation of a direct financial obligation. The company explicitly states it intends to use net proceeds for general corporate purposes and to repay amounts outstanding under its credit agreement, making this a significant debt issuance event that would affect a reasonable investor's assessment of the company's capital structure and financial flexibility.
View raw filing on EDGAR →Axsome issued a press release on August 10, 2026 announcing Q2 2026 financial results, disclosing total net product revenue of $218.4 million (46% YoY growth), with AUVELITY sales of $180.3 million (51% YoY growth), SUNOSI revenue of $35.8 million (20% YoY growth), SYMBRAVO revenue of $2.3 million, and a net loss of $51.3 million. The disclosure includes detailed commercial metrics, operating expenses, cash position, and forward-looking guidance on cash sufficiency.
View raw filing on EDGAR →Village Farms issued a press release on August 10, 2026 announcing its financial results for Q2 2026 ended June 30, 2026, disclosing consolidated net sales of $64 million (27% sequential, 7% YoY growth), net income of $7.1 million, and record cannabis revenues of $53.5 million. The filing explicitly states this is furnished under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for earnings releases on Form 8-K.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure explicitly states that "Jade Biosciences, Inc. (the 'Company') issued a press release announcing the Company's financial results for the quarter ended June 30, 2026," with the press release furnished as Exhibit 99.1. The exhibit contains condensed consolidated financial statements (balance sheet and statement of operations) showing Q2 2026 results including net loss of $55.8 million, R&D expenses of $50.1 million, and cash position of $461.2 million, along with a corporate update on pipeline progress.
View raw filing on EDGAR →Sionna announced topline data from two clinical trials: the Phase 2a PreciSION CF trial of SION-719 failed to meet its key efficacy endpoint (sweat chloride reduction), and the company is discontinuing SION-719 as an add-on therapy. The Phase 1 trial of SION-451 dual combinations achieved safety objectives. The company is preserving capital while evaluating next steps for its SION-451 program. This is a material clinical development milestone and strategic pivot that affects the company's pipeline and capital allocation strategy, but does not fit neatly into specific categories like earnings_release, material_impairment, or workforce_reduction—it is a clinical trial failure with operational/strategic consequences.
View raw filing on EDGAR →This is a press release announcing Sohu.com's unaudited financial results for the second quarter ended June 30, 2026. The document discloses total revenues of US$136 million (up 7% YoY), net income of US$0.2 million (GAAP) and US$0.5 million (non-GAAP), along with detailed segment results, balance sheet data, and forward guidance for Q3 2026. The filing includes condensed consolidated statements of operations and balance sheets, making it a classic quarterly earnings announcement.
View raw filing on EDGAR →The Company issued a press release announcing topline results from its Phase 3 LEVEL clinical trial of TNX-103. Although the primary endpoint was not met (6-minute walk distance improvement), the disclosure of Phase 3 trial results—a major clinical milestone for a development-stage pharmaceutical company—constitutes a material event comparable to an earnings release in terms of investor significance. The results include detailed efficacy, safety, and biomarker data that would materially affect investor assessment of the drug candidate's viability and the company's regulatory path forward.
View raw filing on EDGAR →The Item 2.02 disclosure centers on Apogee's second quarter 2026 financial results, including cash position ($1.3 billion), R&D expenses ($67.3 million), G&A expenses ($24.3 million), and net loss ($85.9 million), furnished as a press release exhibit. While the press release also announces the pending AbbVie acquisition ($135.11/share, ~$10.9 billion equity value), the Item 2.02 classification specifically addresses financial results. The acquisition is material but constitutes a separate M&A event; however, since Item 2.02 is explicitly designated for "Results of Operations and Financial Condition," the earnings_release classification is most appropriate for this Item, though the filing also contains ma_activity elements.
View raw filing on EDGAR →The filing discloses Silence Therapeutics' second quarter 2026 financial and business results via a press release issued on August 10, 2026. The Item 2.02 disclosure includes condensed consolidated statements of operations and balance sheets showing Q2 2026 results (net loss of $12.3 million, R&D expenses of $9.1 million, cash position of $72.1 million) compared to prior-year periods, along with business highlights on clinical programs. This is a standard quarterly earnings release material to investors assessing the company's financial condition and operational progress.
View raw filing on EDGAR →Jazz Pharmaceuticals announced entry into a definitive agreement to acquire Actio Biosciences for $820 million upfront plus up to $500 million in contingent consideration. The press release explicitly states the companies "have entered into a definitive agreement" and describes this as a material strategic expansion of Jazz's rare epilepsy portfolio. This is a classic material acquisition disclosure under Item 1.01 of Form 8-K, disclosed via Item 7.01 Regulation FD Disclosure.
View raw filing on EDGAR →Silence Therapeutics announced positive Phase 2 SANRECO trial results for divesiran in polycythemia vera on August 10, 2026, meeting primary and secondary endpoints with strong efficacy and safety profiles. The disclosure includes trial outcomes, safety findings, and plans for Phase 3 initiation, representing a material clinical milestone for the clinical-stage biotech company.
View raw filing on EDGAR →Oculis has entered into an asset purchase agreement to acquire all worldwide development and commercial rights to Privosegtor from Accure Therapeutics for $3.8 million in cash plus up to 2.05 million ordinary shares. This is a material acquisition of a lead clinical-stage asset (currently in registrational trials with Breakthrough Therapy and PRIME designations) that terminates an existing license agreement and significantly reduces future royalty obligations, directly affecting the company's economic interest in a core pipeline asset.
View raw filing on EDGAR →SES announced the successful completion of Rendez-vous 1 (RDV1), a key validation milestone under the IRIS² programme, confirming programme readiness to move into implementation phase. The disclosure details SES's capital commitment (up to €1.35 billion), deployment of 18 MEO satellites, targeted 2030 service entry, and SES's expanded operational role (payload design, satellite assembly, user terminal development, and operations). This is a material strategic and operational milestone for a major satellite constellation programme, not a discrete M&A transaction, financial obligation, or executive change, but rather a programme validation and operational commitment that affects the company's long-term business roadmap and capital allocation.
View raw filing on EDGAR →This is a clear earnings release disclosing Q2 2026 financial results for the three and six months ended June 30, 2026. The filing explicitly states "Heron Therapeutics Announces Second Quarter 2026 Financial Results" and provides detailed net revenue performance by product line, cash position, and operational highlights. The withdrawal of full-year 2026 guidance and discussion of strategic alternatives add material context, but the core disclosure is the quarterly earnings announcement furnished as Exhibit 99.1.
View raw filing on EDGAR →MarineMax entered into a definitive Agreement and Plan of Merger with Safe Harbor Marinas (a Blackstone Infrastructure portfolio company) on August 9, 2026, whereby Safe Harbor will acquire all outstanding shares of MarineMax common stock for $53.00 per share in an all-cash transaction valued at approximately $1.5 billion. The transaction is a material change of control requiring shareholder approval and is expected to close by year-end 2026, resulting in MarineMax becoming a privately held company.
View raw filing on EDGAR →Beyond Meat entered into a Second Supplemental Indenture on August 10, 2026, amending the terms of its 7.00% Convertible Senior Secured Second Lien PIK Toggle Notes due 2030. The amendment removes restrictions on repurchasing or exchanging the 2027 Notes and extends the make-whole period for 2030 Note conversions, materially modifying the terms of existing debt obligations. While this is technically an amendment rather than a new issuance, it constitutes a material modification of direct financial obligations and falls within the debt_issuance category as the most appropriate classification for debt-related capital structure events.
View raw filing on EDGAR →The filing discloses Cogent Biosciences' financial results for the second quarter ended June 30, 2026, via a press release attached as Exhibit 99.1. The disclosure includes condensed consolidated statements of operations showing Q2 2026 net loss of $96.4 million versus $73.5 million in Q2 2025, along with balance sheet data and detailed business highlights regarding clinical trial progress and regulatory milestones for bezuclastinib. This is a standard quarterly earnings release under Item 2.02.
View raw filing on EDGAR →CoreCivic announced a $500 million accelerated share repurchase (ASR) agreement on August 10, 2026, under which the company will repurchase approximately 12.4 million shares initially, with final settlement by Q2 2027. This capital allocation decision represents a material return of capital to shareholders and includes revised 2026 financial guidance reflecting the impact of the share repurchase program.
View raw filing on EDGAR →Onto Innovation completed its acquisition of a 27% minority equity stake in Rigaku Holdings Corporation for approximately $720 million on August 10, 2026, representing a significant strategic investment that deepens collaboration in semiconductor manufacturing process control technologies.
View raw filing on EDGAR →The filing discloses the appointment of Kashif Rashid as Chief Legal Officer and Corporate Secretary, effective August 10, 2026, following the Board's decision on August 6, 2026. While the section also includes Jeremy Hayden's departure as Chief Legal Officer, the principal disclosed action centers on the appointment of a new executive officer to a key leadership role. The appointment includes detailed employment terms (base salary of $450,000, 50% bonus target, severance provisions) and an RSU award of $1,400,000, making this a material executive appointment that would affect investor assessment of the company's leadership and governance.
View raw filing on EDGAR →The disclosure centers on the Board's appointment of Alan Musso as principal accounting officer effective August 7, 2026, following Greg Tourangeau's departure from that role. While both a departure and an appointment occur, the principal action disclosed is the appointment of Musso to the principal accounting officer position. The appointment of a principal accounting officer is a material governance event affecting the registrant's financial reporting oversight.
View raw filing on EDGAR →Mosaic announced the commencement of cash tender offers to purchase up to $1.4 billion in aggregate principal amount of outstanding debt securities across four series of notes. While this is technically a debt repurchase rather than new debt issuance, the filing explicitly discloses that the Offers are conditioned on Mosaic completing a "proposed registered public offering (the 'New Notes Offering') of new series of senior notes" to finance the tender offer. The material event centers on the creation of new direct financial obligations through the planned debt offering, which is the financing mechanism for the tender offer activity.
View raw filing on EDGAR →Ondas Inc. completed its acquisition of Cyberhawk Holdings Limited on August 10, 2026, acquiring 100% of the company for $118.2 million in cash and 581,732 shares of common stock. The transaction includes inducement equity grants to 47 newly-hired Cyberhawk employees and represents a material strategic expansion into critical infrastructure intelligence and drone inspection markets.
View raw filing on EDGAR →Martin Marietta Materials announced the receipt of all necessary regulatory approvals for its acquisition of Lhoist North America, Inc., with closing expected in Q3 2026. The filing discloses the Securities Sale Agreement dated June 27, 2026, and confirms regulatory approval as of August 5, 2026. This represents a material acquisition activity that would significantly affect a reasonable investor's assessment of the registrant's strategic direction and financial position.
View raw filing on EDGAR →The 6-K furnishes three exhibits: (99.1) a board approval of a capital reconstruction project; (99.2) unaudited operating results for July 2026 and year-to-date through July; and (99.3) a monthly operational and financial status report. Exhibit 99.2 is the dominant disclosure—it reports consolidated revenue (NT$19.88B for July, NT$141.24B YTD), operating income, net income, EBITDA, and EPS for the month and seven-month period. This is a periodic interim financial report (monthly results), not a discrete event. The reconstruction project (99.1) is operational but secondary. The classification reflects the primary substance: a monthly interim financial disclosure.
View raw filing on EDGAR →Bowman Consulting Group Ltd. entered into a definitive Agreement and Plan of Merger with Prive Parent, Inc. (affiliated with Bernhard Capital Partners) on August 10, 2026, whereby the Company will be acquired for $43.00 per share in cash, with expected closing in Q4 2026 or Q1 2027. The transaction is subject to stockholder approval and regulatory clearance, and the Company's stock will be delisted from Nasdaq upon consummation.
View raw filing on EDGAR →Bowman Consulting Group Ltd. disclosed financial results for Q2 2026 ended June 30, 2026 via press release on August 10, 2026, reporting gross contract revenue of $146.1M (+19.7%), net service billing of $129.0M (+19.4%), and backlog of $658.7M (+50.3%).
View raw filing on EDGAR →Medical Properties Trust issued a press release on August 10, 2026 announcing financial results for the three and six months ended June 30, 2026, including net loss of ($0.01) per share and NFFO of $0.15 per share for Q2 2026, with consolidated balance sheets, income statements, and FFO reconciliations.
View raw filing on EDGAR →MPT Operating Partnership and MPT Finance Corporation entered into an exchange and purchase agreement to issue $2.4 billion in aggregate principal amount of new 9.25% senior secured notes due 2032, with proceeds to repay existing 2026 notes and approximately 50% of 2027 notes.
View raw filing on EDGAR →Mark Teixeira resigned from the Company's Board of Trustees and all committees thereof, effective immediately on August 5, 2026. The disclosure explicitly states the resignation was due to his candidacy as the Republican nominee for Texas's 21st congressional district. This is a clear departure of a director from the board, making it an exec_departure event. The materiality is high as board composition changes affect governance and investor assessment of the company.
View raw filing on EDGAR →DynaResource announced a favorable ruling by Mexico's Federal District Court in Amparo proceedings protecting the company's constitutional right to due process regarding eight mining concessions at the San José de Gracia Project. The Court granted constitutional protection and ordered authorities to recommence notification procedures, restoring the company's procedural rights. While the ruling is subject to appeal and does not finally resolve the underlying administrative matter, it is a material legal development affecting the company's core mining assets in Mexico.
View raw filing on EDGAR →The Trust entered into custodial services agreements with Anchorage Digital Bank NA and BitGo Bank & Trust, N.A. on August 7, 2026, and amended its Sponsor Agreement to enable staking of ether, establishing the infrastructure for the Fund's core custody and staking operations.
View raw filing on EDGAR →The Trust commenced its staking program, a material operational initiative that will generate income through Ethereum staking rewards and fund quarterly cash distributions to shareholders.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of the 2026 Annual Meeting of Stockholders held on August 6, 2026, specifically the election of five directors (Ella S. Neyland, Anthony Chereso, Alan Feldman, Michael W. Reid, and Daniel Rigby) with detailed vote tallies showing votes for, against, abstentions, and broker non-votes for each nominee. This is a textbook shareholder vote results disclosure required under Item 5.07.
View raw filing on EDGAR →BlossomHill Therapeutics completed its initial public offering on August 10, 2026, raising approximately $150.0 million in gross proceeds from the sale of 9,375,000 shares at $16.00 per share, fundamentally transforming the company's financial structure and investor base.
View raw filing on EDGAR →